[      home     ]      [  services  ]      [  technologies  ]      [  success stories  ]      [  about us  ]      [  affiliates  ]      [  find out more 

TECHNOLOGIES BIOMEDICAL TECHNOLOGIES GLYCOPROTEINS

Patents: Sleeping Beauties. 
    Awaken the potential inside your
    intellectual property.

FPI's Success Stories
Contact FPI
Check out FPI's focus areas
Download pdf versions of brochures
    and technology offerings

Links to related sites

Opportunities
This opportunity enables the large-scale production of mammalian-like polysaccharides by recombinant DNA technology.

The technology overcomes many of the problems associated with the production of N-linked glycoproteins derived from humans and other mammals.

Using a transferase gene isolated from yeast (Saccharomyces cerevisiae), a process has been developed for efficiently producing an acidic sugar chain in large quantities and high purity. The yeast cells are genetically-engineered with an MNN6-containing plasmid DNA. Its nucleotide sequence is a single-strand, having linear topology, and 1,380 base pairs in length.

Further, the method enables a marker to be produced to function as a label for transport of glycoproteins into mammalian lysosomes.

Go to printable pdf version of this technology


Intellectual Property
Current U.S. patents granted that protect the technology include:

   
 
Patent Key Features
5,854,031
  • Mannose-1-phosphate transferase gene from yeast and its use for producing phosphate-containing acidic sugars
  • Yeast-based, isolated nucleic acid sequence described in Claim 1.
  • Plasmid DNA comprising a mannose-1-phosphate transferase gene from yeast with the sequence of Claim 1.
  • Efficient process for producing the glycoprotein side chain in vivo or in vitro.
  • Mannose moiety removed by acid treatment which provides options for liposomal and lysosomal drug delivery.
   

The inventors have isolated and determined the structure of the mannose-1-phosphate transferase gene (MNN6). MNN6 is involved in the mannose-1-phosphate addition reaction that is a yeast-specific sugar chain reaction. The gene can be used to produce acidic sugar chains, either in vivo or in vitro.

This technology was developed at AIST, Japanís premier, public research organization.

With research facilities and more than 3,200 employees across Japan, AIST is an organization that comprises 15 research institutes previously under the former Agency of Industrial Science and Technology in the Ministry of International Trade and Industry and the Weights and Measures Training Institute.

AIST is seeking to license these technologies and assist with their commercialization. A number of investment options are currently under consideration.

Consideration will be provided to a range of financial, strategic, and commercial investment partnerships.

Contact
Michael F Allan
First Principals, Inc.
1768 East 25th Street
Cleveland, Ohio 44114
216-881-8526 - Phone
216-881-8522 - Fax
Email: info@firstprmailto:info@firstprincipals.comincipals.com

   

First Principals, Inc.   1768 East 25th Street  Cleveland, Ohio 44114   216.881.8520 phone   216.881.8522 fax   Email: info@firstprincipals.com

[home] [services] [technologies] [success stories] [about us] [affiliates] [find out more]